Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with NRAS wild-type or mutant melanoma from a phase I study.

被引：0
|
作者：
Means-Powell, Julie Ann
Adjei, Alex A.
Puzanov, Igor
Dy, Grace K.
Goff, Laura Williams
Ma, Wen Wee
Fetterly, Gerald J.
Michael, Shaunita A.
Chai, Feng
Lamar, Maria
Schwartz, Brian E.
Sosman, Jeffrey Alan
机构：
[1] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[2] Roswell Pk Canc Inst, Buffalo, NY 14263 USA
[3] ArQule Inc, Woburn, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8519
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase I/II study of panitumumab (PANI) combined with trifluridine/tipiracil (FTD/TPI) in patients (pts) with previously treated RAS wild-type (wt) metastatic colorectal cancer (mCRC): Final results of APOLLON study.
    Komatsu, Yoshito
    Kato, Takeshi
    Kagawa, Yoshinori
    Yoshino, Takayuki
    Kuboki, Yasutoshi
    Gamoh, Makio
    Yasui, Hirofumi
    Yamazaki, Kentaro
    Satake, Hironaga
    Goto, Masahiro
    Tanioka, Hiroaki
    Oki, Eiji
    Kotaka, Masahito
    Makiyama, Akitaka
    Denda, Tadamichi
    Soeda, Junpei
    Shibuya, Kazunori
    Iwata, Masaru
    Oba, Koji
    Yamaguchi, Kensei
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [32] Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma A Pooled Analysis of 4 Clinical Trials
    Larkin, James
    Lao, Christopher D.
    Urba, Walter J.
    McDermott, David F.
    Horak, Christine
    Jiang, Joel
    Wolchok, Jedd D.
    JAMA ONCOLOGY, 2015, 1 (04) : 433 - 440
  • [33] A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study)
    Yoshioka, H.
    Azuma, K.
    Yamamoto, N.
    Takahashi, T.
    Nishio, M.
    Katakami, N.
    Ahn, M. J.
    Hirashima, T.
    Maemondo, M.
    Kim, S. W.
    Kurosaki, M.
    Akinaga, S.
    Park, K.
    Tsai, C. M.
    Tamura, T.
    Mitsudomi, T.
    Nakagawa, K.
    ANNALS OF ONCOLOGY, 2015, 26 (10) : 2066 - 2072
  • [34] Safety of ipilimumab in patients (pts) with untreated, advanced melanoma alive beyond 2 years: Results from a phase III study.
    Thomas, Luc
    Wolchok, Jedd D.
    Garbe, Claus
    Lebbe, Celeste
    Bondarenko, Igor
    Rodrigues, Kristen
    Konto, Cyril
    Chin, Kevin M.
    Francis, Stephen
    Robert, Caroline
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [35] A phase I/IIa study of cetuximab combined with fruquintinib in the previously treated RAS/BRAF wild-type metastatic colorectal cancer: Results of the CEFRU study.
    Li, Yong
    Zhang, Haibo
    Huang, Ling
    Liu, Yi-hong
    Chen, Xian
    Qu, Xin
    Liu, Li-rong
    Hou, Fangfang
    Ye, Yongsong
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [36] Efficacy and safety of tislelizumab plus cetuximab and irinotecan in patients with previously treated RAS wild-type advanced colorectal cancer: A phase II, single-arm study.
    Xu, Xiaojing
    Yu, Yiyi
    Wang, Yan
    Cui, Yuehong
    Li, Wei
    Liang, Li
    Li, Qian
    Yu, Shan
    Feng, Yi
    Liu, Qing
    Zhang, Pengfei
    Lv, Minzhi
    Liu, Tianshu
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 125 - 125
  • [37] Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition
    Rimassa, Lorenza
    Bozzarelli, Silvia
    Pietrantonio, Filippo
    Cordio, Stefano
    Lonardi, Sara
    Toppo, Laura
    Zaniboni, Alberto
    Bordonaro, Roberto
    Di Bartolomeo, Maria
    Tomasello, Gianluca
    Dadduzio, Vincenzo
    Tronconi, Maria Chiara
    Piombo, Chiara
    Giordano, Laura
    Gloghini, Annunziata
    Di Tommaso, Luca
    Santoro, Armando
    CLINICAL COLORECTAL CANCER, 2019, 18 (02) : 125 - +
  • [38] Phase II single-arm study of palbociclib and cetuximab rechallenge in KRAS/NRAS/BRAF wild-type (KRAS WT) metastatic colorectal cancer (mCRC) patients (pts)
    Sorah, Jonathan D.
    Moore, Dominic T.
    Reilley, Matthew
    Salem, Mohamed E.
    Sanoff, Hanna Kelly
    Triglianos, Tammy
    McRee, Autumn Jackson
    Lee, Michael Sangmin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [39] Survival outcomes in patients (pts) with KRAS/NRAS (RAS) wild-type (WT) metastatic colorectal cancer (mCRC) and non-liver-limited disease (non-LLD): Data from the PRIME study.
    Douillard, Jean-Yves
    Tabernero, Josep
    Siena, Salvatore
    Peeters, Marc
    Koukakis, Reija
    Terwey, Jan-Henrik
    Sidhu, Roger
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [40] Salvage therapy for metastatic acral or mucosal melanoma: Efficacy and safety analysis of nab-paclitaxel/carboplatin combined with bevacizumab in c-kit/BRAF wild-type pts.
    Cui, Chuan Liang
    Li, Si Ming
    Si, Lu
    Chi, Zhihong
    Sheng, Xi Nan
    Mao, Li Li
    Lian, Bin
    Wang, Xuan
    Tang, Bi Xia
    Guo, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345